{"id":"matching-placebo-to-quetiapine-xr","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebos are inert formulations manufactured to be identical in appearance, taste, and administration schedule to the active drug being tested, enabling double-blind study designs. In this case, the placebo matches Quetiapine XR, an extended-release atypical antipsychotic that antagonizes dopamine and serotonin receptors. The placebo itself contains no active pharmaceutical ingredient and serves as the control arm in Phase 3 trials.","oneSentence":"This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:18.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial)"}]},"trialDetails":[{"nctId":"NCT04513912","phase":"PHASE3","title":"A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Depressive Disorder, Major","enrollment":757},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT01725282","phase":"PHASE2","title":"Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-12-14","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT01256177","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"Bipolar Depression","enrollment":361},{"nctId":"NCT00790192","phase":"PHASE3","title":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia","enrollment":488},{"nctId":"NCT00619892","phase":"PHASE4","title":"A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2008-02","conditions":"Panic Disorder","enrollment":26},{"nctId":"NCT00631748","phase":"NA","title":"Quetiapine for the Reduction of Cocaine Use","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2008-02","conditions":"Cocaine Dependence, Cocaine Abuse, Cocaine Addiction","enrollment":60},{"nctId":"NCT00773162","phase":"PHASE3","title":"Flushing in Social Anxiety Disorder on Seroquel","status":"COMPLETED","sponsor":"START Clinic for Mood and Anxiety Disorders","startDate":"2008-10","conditions":"Social Anxiety Disorder","enrollment":21},{"nctId":"NCT01213836","phase":"PHASE4","title":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00389064","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Anxiety Disorders","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching placebo to Quetiapine XR","genericName":"Matching placebo to Quetiapine XR","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes. Used for Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}